Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - disodium gadoxetate, quantity: 181.43 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; trisodium caloxetate; trometamol; sodium hydroxide - this medicinal product is for diagnostic use only. primovist is indicated for use in adults for the enhancement of magnetic resonance imaging (mri) of focal liver lesion

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - disodium gadoxetate, quantity: 181.43 mg/ml - injection, solution - excipient ingredients: water for injections; trometamol; trisodium caloxetate; hydrochloric acid; sodium hydroxide - this medicinal product is for diagnostic use only. primovist is indicated for use in adults for the enhancement of magnetic resonance imaging (mri) of focal liver lesion

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 1000 iu - diluent, not applicable - excipient ingredients: water for injections - for the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). it may also be used in patients with factor viii inhibitors (neutralising antibodies) who continue to respond to infused factor viii. these products do not contain von willebrand factor, and hence are not indicated in von willebrand's disease.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 250 iu - diluent, not applicable - excipient ingredients: water for injections - indications: for the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).it may also be used in patients with factor viii inhibitors (neutralising antibodies) who continue to respond to infused factor viii. these products do not contain von willebrand factor, and hence are not indicated in von willebrand's disease.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 500 iu - diluent, not applicable - excipient ingredients: water for injections - indications: for the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). it may also be used in patients with factor viii inhibitors (neutralising antibodies) who continue to respond to infused factor viii. these products do not contain von willebrand factor, and hence are not indicated in von willebrand's disease.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 498.72 mg/ml - injection, solution - excipient ingredients: water for injections; trometamol; sodium calcium edetate; dilute hydrochloric acid; sodium hydroxide - indications: ultravist is indicted for all angiographic and urographic examinations and for contrast enhancements in computerised tomography. ultravist 240 is additionally indicated for lumbar myelography in adults.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 498.72 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; water for injections; trometamol; sodium calcium edetate; sodium hydroxide - indications: ultravist is indicated for all angiographic and urographic examinations and for contrast enhancements in computerised tomography. ultravist 240 is additionally indicated for lumbar myelography in adults.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; calcobutrol; trometamol - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: calcobutrol; trometamol; water for injections; hydrochloric acid - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; hydrochloric acid; calcobutrol; water for injections - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement